MONROVIA, CA, July 17, 2011
/24-7PressRelease/ -- Klaus D. Mendla, Head of Global Business Development and Licensing CNS at Boehringer Ingelheim, will give a featured presentation on "Sincerely, Yours - Partnering with Boehringer Ingelheim in the CNS Space" at the 4th CNS Partnering and Deal-making Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC.
Klaus Mendla will outline Boehringer Ingelheim's partnering strategy in the indication areas of chronic pain, neurodegenerative diseases (core indications: AD and Parkinson's disease), and psychiatric disorders (core indications: schizophrenia and depression). Boehringer Ingelheim is interested in compounds with a novel mode of action and a sound scientific rationale for improved efficacy and/or safety/tolerability compared to current standards of care. In addition to the level of scientific and medical innovation, the overall attractiveness of a licensing candidate would clearly benefit from a combination with suitable biomarkers and predictive preclinical models. For each of the core indications for CNS Licensing, Klaus will also discuss Target Licensing Product Profiles (TLPP).
Highlights of Klaus Mendla's presentation:
• Why does the CNS market represent an attractive investment opportunity for Pharma?
• What are the key unmet medical needs in the treatment of chronic pain, neurodegenerative diseases, and psychiatric disorders?
• What kind of partnering opportunities in the CNS space is Boehringer Ingelheim interested in?
Klaus Mendla is Head of Global Business Development and Licensing CNS at Boehringer Ingelheim. He leads the cross-functional CNS Advisory Team responsible for global licensing activities in the therapeutic area Central Nervous System Diseases (covering projects from preclinical leads to late-stage clinical and marketed products). Since joining Boehringer Ingelheim in 1985, he has held several positions in Research and Development within the corporation. Before joining Boehringer Ingelheim's International Business Development and Licensing organization, Dr. Mendla was director of the company's Neurodegeneration Research Group.
His current focus is on licensing projects in the area of neurodegenerative diseases (including Alzheimer's and Parkinson's disease), chronic pain, and psychiatric disorders.
The 4th CNS Partnering and Deal-making Conference gives global biotechnology and pharmaceutical companies in the CNS industry an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant CNS Disease issues and partnerships that will affect the industry.
This event also provides a unique venue for attendees to learn about CNS Diseases business trends, the CNS disease market, and novel technologies that shape the industry. The conference is part of the CNS Diseases World Summit, which consists of 3 tracks including the "5th Neurodegenerative Conditions Research and Development" and "Advances in Neuropsychiatric Treatment".
The sessions for the conferences are:
Plenary Keynote Session
Investments and Partnerships in the CNS Space
Addressing Regulatory and Financial Decisions for Investments and Startups
Recent Advances in CNS Development
Case Studies in the Clinical Space
Strategic Direction in Neuroscience
Current Trends and Recent Deals
For more information, please visit http://www.gtcbio.com
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Rania Hafez:- Maureen Gibbons at BMS, to speak at Life Science Legal Strategy Conference in San Diego on June 7-8
- Brad Spellberg to speak at 9th Anti-infectives Partnering conference July 9-10, 2012 California
- Patrick Terry, Scientia Advisors, presents at Genome-wide Partnering & Deal-making, May 30-31, Boston
- Edmond Yunis to speak at Antibody Conference June 7-8, 2012 in San Diego, CA
- Gail Nunlee-Bland, MD, Howard University Hospital to speak at conference, May 15-17, in Atlanta, GA
- The Joint Commission to speak at Cardiac Centers of Excellence Conference
- Alexander Meissner to speak at 2nd Epigenetics Drug Discovery conference May 30-31, 2012 Boston, MA
- Craig C. Mello to speak at 3rd RNAi Research and Therapeutics conference May 30-31, 2012 Boston, MA
- Nathanael Gray of DFCI to Speak at the 7th Protein Kinases Conference (May 30-31, 2012 in Boston, MA)
- The Joint Commission to speak at Healthcare Centers of Excellence Summit
